The United States Patent and Trademark Office has issued U.S. Patent No. 12,544,407 B2 , dated February 10, 2026, further strengthening FibroBiologics’ intellectual property portfolio in regenerative ...
FibroBiologics will present on fibroblast-based therapies for chronic diseases at a conference in Freiburg, Germany, on March 27, 2025. FibroBiologics, Inc., a biotechnology company focused on ...
FibroBiologics, Inc. Announces Investor Webinar on Innovative Fibroblast-Based Cell Therapy Platform
FibroBiologics, Inc., a clinical-stage biotechnology company focused on developing therapies for chronic diseases through fibroblasts, announced an investor webinar scheduled for July 10, 2025, at ...
Jen Davis (left) and Bella Reichardt (right) conducting research in a lab for genetic engineering of heart fibroblasts.at the UW Medicine Institute for Stem Cell and Regeneration Medicine. Fibroblasts ...
FibroBiologics is planning a prospective, multicenter, open-label clinical trial evaluating the safety, tolerability, and efficacy of CYWC628 in treating refractory diabetic foot ulcers with up to 12 ...
Researchers at the Cancer Research Institute and the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results